• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

iScience . Evolution of protective SARS-CoV-2-specific B and T cell responses upon vaccination and Omicron breakthrough infection

tetano

Editor, Senior Moderator
iScience


. 2024 May 28;27(6):110138.
doi: 10.1016/j.isci.2024.110138. eCollection 2024 Jun 21. Evolution of protective SARS-CoV-2-specific B and T cell responses upon vaccination and Omicron breakthrough infection

Mohamed I M Ahmed[SUP] 1 2 [/SUP], Sebastian Einhauser[SUP] 3 [/SUP], Clemens Peiter[SUP] 4 [/SUP], Antonia Senninger[SUP] 3 [/SUP], Olga Baranov[SUP] 1 2 [/SUP], Tabea M Eser[SUP] 1 2 5 [/SUP], Manuel Huth[SUP] 4 6 [/SUP], Laura Olbrich[SUP] 1 2 [/SUP], Noemi Castelletti[SUP] 1 [/SUP], Raquel Rubio-Acero[SUP] 1 [/SUP], George Carnell[SUP] 7 [/SUP], Jonathan Heeney[SUP] 7 [/SUP], Inge Kroidl[SUP] 1 2 [/SUP], Kathrin Held[SUP] 1 2 [/SUP], Andreas Wieser[SUP] 1 2 5 [/SUP], Christian Janke[SUP] 1 [/SUP], Michael Hoelscher[SUP] 1 2 5 8 [/SUP], Jan Hasenauer[SUP] 4 6 9 [/SUP], Ralf Wagner[SUP] 3 10 [/SUP], Christof Geldmacher[SUP] 1 2 5 [/SUP]; KoCo19/ORCHESTRA working group



Affiliations
Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron breakthrough infection (BTI) induced better protection than triple vaccination. To address the underlying immunological mechanisms, we studied antibody and T cell response dynamics during vaccination and after BTI. Each vaccination significantly increased peak neutralization titers with simultaneous increases in circulating spike-specific T cell frequencies. Neutralization titers significantly associated with a reduced hazard rate for SARS-CoV-2 infection. Yet, 97% of triple vaccinees became SARS-CoV-2 infected. BTI further boosted neutralization magnitude and breadth, broadened virus-specific T cell responses to non-vaccine-encoded antigens, and protected with an efficiency of 88% from further infections by December 2022. This effect was then assessed by utilizing mathematical modeling, which accounted for time-dependent infection risk, the antibody, and T cell concentration at any time point after BTI. Our findings suggest that cross-variant protective hybrid immunity induced by vaccination and BTI was an important contributor to the reduced virus transmission observed in Bavaria in late 2022 and thereafter.

Keywords: immunology; microbiology; virology.

 
Back
Top Bottom